Neovasc_Logo-web-header.jpg
Neovasc Announces New Appointments in Regulatory and Clinical Leadership
July 13, 2021 09:05 ET | Neovasc, Inc.
Neovasc Team Grows with Addition of Industry Veterans Lisa Becker as VP, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as VP of Clinical Affairs VANCOUVER and MINNEAPOLIS, July 13,...
PAVMEDLOGONEW15OCT2018.png
PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
June 10, 2021 09:30 ET | PAVmed Inc.
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Hold Business Update Conference Call on May 17, 2021
May 03, 2021 09:30 ET | PAVmed Inc.
Company conference call and webcast at 4:30 PM EDT NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,...
PAVMEDLOGONEW15OCT2018.png
PAVmed Retires Convertible Debt
March 03, 2021 09:30 ET | PAVmed Inc.
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Announces Proposed Public Offering of Common Stock
February 22, 2021 16:13 ET | PAVmed Inc.
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Hold Business Update Conference Call on February 22, 2021
February 09, 2021 09:30 ET | PAVmed Inc.
NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 08, 2021 10:53 ET | PAVmed Inc.
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
August 18, 2020 16:14 ET | PAVmed Inc.
Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,...
Neovasc_Logo-web-header.jpg
Neovasc Announces Partial Prepayment of Convertible Debenture
August 17, 2020 09:00 ET | Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”)...
Neovasc_Logo-web-header.jpg
Neovasc Announces US$12.6 Million Registered Direct Offering Priced At-the-Market
August 10, 2020 08:00 ET | Neovasc, Inc.
VANCOUVER, CANADA, Aug. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive...